NFKB1 and prostate carcinoma: On this latter, the major CK2-site is Ser529 (Wang et al., 2000), whose diminished phosphorylation in response to CX-4945 (with consequent attenuation of NF-κB activity) was described as instrumental for restoring sensitivity to anti-androgens of castration-resistant prostate cancer cells [34].